Zynex Announces 70% Order Growth and Increases Q3 2021 Adjusted EBITDA Estimate

Rhea-AI Summary

Zynex, Inc. (NASDAQ: ZYXI) announced a strong performance for Q3 2021, reporting a 70% year-over-year order growth and projecting Q3 revenue between $34.5 million and $36 million. The company has increased its Adjusted EBITDA estimate to $9 million to $10 million, up from a prior estimate of $5 million to $6 million. For the full year, Zynex estimates revenue between $130 million and $137.5 million, reflecting an increase of 62% to 72% compared to the previous year. This growth supports Zynex's strategy to provide non-opioid pain management solutions.

Positive

• 70% year-over-year order growth in Q3 2021.
• Adjusted EBITDA forecast increased to $9 million to $10 million.
• Full year revenue estimate of $130 million to $137.5 million, up 62% to 72% from last year.

Negative

• None.

ENGLEWOOD, Colo., Oct. 13, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders and an increased Adjusted EBITDA estimate for Q3 2021.

Thomas Sandgaard, CEO of Zynex said: "Our order growth in Q3 remained strong at 70% year over year and 134% for the first three quarters of 2021. We are pleased with our continued revenue growth and the related profitability as we continue to leverage the sales investments we've made over the last couple years. Q3 2021 Adjusted EBITDA is by far the largest in company history and reaffirms our growth strategy. As our reps continue to get more efficient, our profitability will remain strong.

We are confirming our previous revenue estimate for the third quarter of 2021 of between $34.5 and $36.0 million. Q3 2021 Adjusted EBITDA is now expected to come in between $9.0 and $10.0 million compared to the previous estimate of $5.0 to $6.0 million.

The company's current full year 2021 revenue estimate is currently between $130.0 and $137.5 million. The revenue estimate is approximately 62% to 72% above last year's full year revenue of $80.1 million. The 2021 full year estimated Adjusted EBITDA is currently estimated between $16.5 to $21.5 million compared to 2020's full year Adjusted EBITDA of $13.7 million.

The company will provide updated full year revenue and Adjusted EBITDA estimates with its Q3 2021 earnings release in late October.

Our prescription-strength NexWave device is a healthy alternative to prescribing opioids as the first line of defense when treating pain.

We continue to advocate for pain patients, and for physicians to prescribe our NexWave technology as the first line of defense in treating chronic and acute pain without side effects. We are dedicated to promoting our technology in an effort to remove patient addiction and other side effects from prescription opioids."

About Zynex 

Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the Company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex also has a fluid monitor for use in hospitals and surgery centers. For additional information, please visit: Zynex.com.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, forecasts, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore you should not rely on any of these forward looking statements.  The Company makes no express or implied representation or warranty as to the completeness of forward looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance companies, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy and other risks described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2020 as well as our quarterly reports on Form 10-Q and current reports on Form 8-K.

Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact:
Zynex, Inc.
(800) 495-6670

Investor Relations Contact:
Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/zynex-announces-70-order-growth-and-increases-q3-2021-adjusted-ebitda-estimate-301399294.html

SOURCE Zynex